A systematic review of religious beliefs about major end-of-life issues in the five major world religions
R Chakraborty, AR El-Jawahri, MR Litzow… - … & supportive care, 2017 - cambridge.org
Objective: The objective of this study was to examine the religious/spiritual beliefs of
followers of the five major world religions about frequently encountered medical situations at …
followers of the five major world religions about frequently encountered medical situations at …
Quality of life and mood of patients and family caregivers during hospitalization for hematopoietic stem cell transplantation
AR El‐Jawahri, LN Traeger, K Kuzmuk, JR Eusebio… - Cancer, 2015 - Wiley Online Library
BACKGROUND We conducted a study to investigate the impact of hospitalization for
hematopoietic stem cell transplantation (HCT) on the quality of life (QOL) and mood of …
hematopoietic stem cell transplantation (HCT) on the quality of life (QOL) and mood of …
Quality of life and mood predict posttraumatic stress disorder after hematopoietic stem cell transplantation
AR El‐Jawahri, HB Vandusen, LN Traeger… - Cancer, 2016 - Wiley Online Library
BACKGROUND During hospitalization for hematopoietic stem cell transplantation (HCT),
patients experience a steep deterioration in quality of life (QOL) and mood. To our …
patients experience a steep deterioration in quality of life (QOL) and mood. To our …
Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia
BACKGROUND Health care utilization in older adults (age≥ 60 years) with acute myeloid
leukemia (AML) has not been well studied. METHODS We conducted a retrospective …
leukemia (AML) has not been well studied. METHODS We conducted a retrospective …
[HTML][HTML] Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)
In addition to remarkable antitumor activity, chimeric antigen receptor (CAR) T-cell therapy is
associated with acute toxicities such as cytokine release syndrome (CRS) and immune …
associated with acute toxicities such as cytokine release syndrome (CRS) and immune …
Symptom burden in patients with cancer who are experiencing unplanned hospitalization
RA Newcomb, RD Nipp, LP Waldman, JA Greer… - Cancer, 2020 - Wiley Online Library
Background Inpatient supportive care programs often target patients with advanced solid
tumors. To the authors' knowledge, few studies to date have characterized symptom burden …
tumors. To the authors' knowledge, few studies to date have characterized symptom burden …
Pain syndromes and management in adult hematopoietic stem cell transplantation
JD Ma, AR El-Jawahri, TW LeBlanc… - Hematology …, 2018 - hemonc.theclinics.com
Hematopoietic stem cell transplant (HSCT) is a high-risk procedure focused on the
possibility of cure in patients with otherwise incurable benign or malignant disorders. The …
possibility of cure in patients with otherwise incurable benign or malignant disorders. The …
Integration of palliative care into acute myeloid leukemia care
Objective To provide an overview of the past, present, and future of the integration of
palliative care services for patients with hematologic malignancies, such as acute myeloid …
palliative care services for patients with hematologic malignancies, such as acute myeloid …
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
JD Soumerai, A Rosenthal, S Harkins… - Blood, The Journal …, 2022 - ashpublications.org
COI notes: Jacob D. Soumerai reports consulting fees from Abbvie, AstraZeneca, Beigene,
Biogen, Bristol Myers Squibb, Roche, TG Therapeutics, and Verastem, and research funding …
Biogen, Bristol Myers Squibb, Roche, TG Therapeutics, and Verastem, and research funding …
[HTML][HTML] Association of bridging therapy utilization with clinical outcomes in patients receiving chimeric antigen receptor (CAR) T-cell therapy
PC Johnson, C Jacobson, A Yi… - … for ImmunoTherapy of …, 2022 - ncbi.nlm.nih.gov
Background Chimeric antigen receptor (CAR) T-cell therapy recipients may receive bridging
therapy while awaiting product manufacturing to control disease. Yet, data are lacking …
therapy while awaiting product manufacturing to control disease. Yet, data are lacking …